GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 34.72 Million EUR | -15.75% |
| 2022 | 41.22 Million EUR | 1.38% |
| 2021 | 40.65 Million EUR | 13.91% |
| 2020 | 35.69 Million EUR | 72.13% |
| 2019 | 20.73 Million EUR | 58.19% |
| 2018 | 13.1 Million EUR | 81.67% |
| 2017 | 7.21 Million EUR | 22.51% |
| 2016 | 5.89 Million EUR | -15.66% |
| 2015 | 6.98 Million EUR | 64.81% |
| 2014 | 4.23 Million EUR | 122.31% |
| 2013 | 1.9 Million EUR | 1399.9% |
| 2012 | 127.08 Thousand EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 39.82 Million EUR | 0.0% |
| 2024 Q1 | 39.82 Million EUR | 0.05% |
| 2023 Q4 | 39.8 Million EUR | -0.09% |
| 2023 FY | 34.72 Million EUR | -15.75% |
| 2023 Q3 | 39.83 Million EUR | -9.06% |
| 2023 Q1 | 43.8 Million EUR | 6.27% |
| 2023 Q2 | 43.8 Million EUR | 0.0% |
| 2022 Q2 | 37.32 Million EUR | 0.0% |
| 2022 Q3 | 41.22 Million EUR | 10.45% |
| 2022 Q1 | 37.32 Million EUR | -8.21% |
| 2022 Q4 | 41.22 Million EUR | 0.0% |
| 2022 FY | 41.22 Million EUR | 1.38% |
| 2021 Q1 | 34.46 Million EUR | -3.44% |
| 2021 Q3 | 40.65 Million EUR | 17.97% |
| 2021 Q2 | 34.46 Million EUR | 0.0% |
| 2021 FY | 40.65 Million EUR | 13.91% |
| 2021 Q4 | 40.65 Million EUR | -0.0% |
| 2020 Q3 | 35.61 Million EUR | 29.01% |
| 2020 Q2 | 27.6 Million EUR | -0.0% |
| 2020 FY | 35.69 Million EUR | 72.13% |
| 2020 Q1 | 27.6 Million EUR | 33.12% |
| 2020 Q4 | 35.69 Million EUR | 0.23% |
| 2019 Q3 | 21.96 Million EUR | 40.41% |
| 2019 Q4 | 20.73 Million EUR | -5.59% |
| 2019 FY | 20.73 Million EUR | 58.19% |
| 2019 Q1 | 15.64 Million EUR | 19.33% |
| 2019 Q2 | 15.64 Million EUR | 0.01% |
| 2018 Q3 | 13.1 Million EUR | 60.63% |
| 2018 Q4 | 13.1 Million EUR | 0.0% |
| 2018 FY | 13.1 Million EUR | 81.67% |
| 2018 Q1 | 8.16 Million EUR | 13.1% |
| 2018 Q2 | 8.16 Million EUR | 0.0% |
| 2017 Q3 | 7.21 Million EUR | -7.51% |
| 2017 Q4 | 7.21 Million EUR | 0.0% |
| 2017 Q1 | 7.8 Million EUR | 32.45% |
| 2017 Q2 | 7.8 Million EUR | 0.0% |
| 2017 FY | 7.21 Million EUR | 22.51% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 5.89 Million EUR | -15.66% |
| 2016 Q4 | 5.89 Million EUR | -0.01% |
| 2016 Q3 | 5.89 Million EUR | 0.0% |
| 2015 Q3 | 6.98 Million EUR | 36.25% |
| 2015 Q1 | 5.12 Million EUR | 20.96% |
| 2015 FY | 6.98 Million EUR | 64.81% |
| 2015 Q2 | 5.12 Million EUR | 0.0% |
| 2015 Q4 | 6.98 Million EUR | -0.0% |
| 2014 FY | 4.23 Million EUR | 122.31% |
| 2014 Q4 | 4.23 Million EUR | 0.0% |
| 2014 Q3 | 4.23 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | 1.9 Million EUR | 1399.9% |
| 2012 FY | 127.08 Thousand EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -402.416% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 73.501% |
| Adocia SA | 31.87 Million EUR | -8.965% |
| Aelis Farma SA | 13.08 Million EUR | -165.497% |
| Biophytis S.A. | 15.84 Million EUR | -119.112% |
| Advicenne S.A. | 24.37 Million EUR | -42.458% |
| genOway Société anonyme | 14.45 Million EUR | -140.167% |
| IntegraGen SA | 5.97 Million EUR | -480.739% |
| Medesis Pharma S.A. | 6.42 Million EUR | -440.398% |
| Neovacs S.A. | 3.71 Million EUR | -835.502% |
| NFL Biosciences SA | 3.62 Million EUR | -859.128% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -412.02% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -949.12% |
| Sensorion SA | 13.22 Million EUR | -162.541% |
| Theranexus Société Anonyme | 5.01 Million EUR | -592.298% |
| TME Pharma N.V. | 2.78 Million EUR | -1146.93% |
| Valbiotis SA | 13.7 Million EUR | -153.334% |
| TheraVet SA | 1.48 Million EUR | -2238.53% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -69.665% |
| argenx SE | 402.79 Million EUR | 91.379% |
| BioSenic S.A. | 32.26 Million EUR | -7.634% |
| Celyad Oncology SA | 9.97 Million EUR | -248.036% |
| DBV Technologies S.A. | 38.74 Million USD | 10.371% |
| Galapagos NV | 1.56 Billion EUR | 97.777% |
| Genfit S.A. | 105.92 Million EUR | 67.214% |
| GeNeuro SA | 20.13 Million EUR | -72.429% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -303.24% |
| Innate Pharma S.A. | 132.29 Million EUR | 73.75% |
| Inventiva S.A. | 101.59 Million EUR | 65.818% |
| MaaT Pharma SA | 22.46 Million EUR | -54.583% |
| MedinCell S.A. | 77.77 Million EUR | 55.347% |
| Nanobiotix S.A. | 95.74 Million EUR | 63.728% |
| Onward Medical N.V. | 25.69 Million EUR | -35.135% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -38.214% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 41.219% |
| Oxurion NV | 19.73 Million EUR | -75.958% |
| Pharming Group N.V. | 228.28 Million EUR | 84.788% |
| Poxel S.A. | 53.9 Million EUR | 35.573% |
| Transgene SA | 26.51 Million EUR | -30.961% |
| Financière de Tubize SA | 123.65 Million EUR | 71.915% |
| UCB SA | 6.56 Billion EUR | 99.471% |
| Valneva SE | 341.14 Million EUR | 89.82% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -663.734% |